Skip to content

Pennsylvania · Nonprofit

EYE TUMOR RESEARCH FOUNDATION INC

EYE TUMOR RESEARCH FOUNDATION INC (Pennsylvania) receives grants from 7 organizations whose IRS filings report $145,478 to it, the largest being FILKINS FAMILY FOUNDATION ($76,145). 6 of them have funded it in more than one year.

Revenue FY2024
$139k
Funders on record
7
Grants received
$145k
Net assets
$876k
6/7 repeat funderspeak grant-dependency 15%
01What it does

What Eye Tumor Research Foundation Inc does

Mission

Research and education regarding malignant melanoma and retinoblastoma tumors of the eye. Objective is to better treat eye tumors and ultimately decrease mortality rates

As stated on its FY2024 Form 990.

Program

  1. Research and education regarding malignant melanoma and retinoblastoma tumors of the eye.

    $173,532 spent
    100% of program spending

The program described on its FY2024 Form 990. Program spending in total: $173,532.

02The organization over time

The organization over time

Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended.

100 = 20172017 Revenue 100 ($174k) Expenses 100 ($85k) Net assets 100 ($768k)2018 Revenue 79 ($137k) Expenses 116 ($99k) Net assets 103 ($787k)2019 Revenue 84 ($147k) Expenses 127 ($108k) Net assets 110 ($842k)2020 Revenue 98 ($171k) Expenses 138 ($117k) Net assets 117 ($898k)2021 Revenue 117 ($204k) Expenses 149 ($127k) Net assets 128 ($982k)2022 Revenue 65 ($112k) Expenses 194 ($166k) Net assets 112 ($863k)2023 Revenue 88 ($153k) Expenses 245 ($208k) Net assets 114 ($874k)2024 Revenue 80 ($139k) Expenses 215 ($183k) Net assets 114 ($876k)
'17'18'19'20'21'22'23'24
Revenue (80)Expenses (215)Net assets (114)

Balance sheet

Total assets and total liabilities at each year end, in dollars. The largest one-year move in total assets was 2021 to 2022, from $982k to $863k (−12%).

$768k
$787k
$842k
$898k
$982k
$863k
$874k
$876k
'17'18'19'20'21'22'23'24
Total assetsTotal liabilities

How it's funded, over time

Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.

2017
2018
2019
2020
2021
2022
2023
2024
ContributionsProgram revenueInvestmentOther

Surplus & reserves

Operating surplus or deficit each year, and months of liquidity in hand. 3 of the last 8 reported years ran a deficit.

$89k
’17
$39k
’18
$39k
’19
$54k
’20
$77k
’21
−$53k
’22
−$56k
’23
−$44k
’24
14
months of
reserve

Leadership and staff

The officers, directors, trustees and key employees listed on each return. Joined and no longer listed compare each filing with the year before, matching people by surname and first initial; a year after a gap, or a roster under three people, has no comparison.

'17'18'19'20'21'22'23'24
Listed33333332
Joined·+0+0+0+0+0+0·
No longer listed·000000·
03Who funds it

Who funds it, year by year

2017 → 2023: the base held at 3 funders, grant income fell $21k → $18k.

2 of 7 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 14% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.

From the IRS filings of EYE TUMOR RESEARCH FOUNDATION INC’s funders (the co-funder graph). Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

How concentrated its funding is

EYE TUMOR RESEARCH FOUNDATION INC leans on a few funders — its largest provides 52% of grant income and the top three 83%; half comes from just 1 funder.

the vertical line marks half of all grant income — 1 funder to its left

52%
largest funder
83%
top three
~3
effective funders

Largest funder’s share by year: 2017 48% · 2018 67% · 2019 67% · 2020 99% · 2021 99% · 2022 60% · 2023 84% — growing more concentrated.

“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

Where its funders are

EYE TUMOR RESEARCH FOUNDATION INC draws 100% of its grant income from funders outside Pennsylvania, across 5 states in all.

NY
OH
CT
NE
VA

In-state vs out-of-state, by year

’17
’18
’19
’20
’21
’22
’23
Pennsylvania out of state home

Funder states come from each funder’s own filing. $20k arriving through sponsors registered in 2 states is excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

04Its place in the field

Organizations like EYE TUMOR RESEARCH FOUNDATION INC

Organizations whose mission and program text most resemble this one, by semantic similarity over every organization in the US filings — the closest peers, and often the clearest route to shared or prospective funders.

In Pennsylvania

Nationally

05Profile & governance

Read directly from this organization’s own Form 990, as neutral context.

Where the money goes

95% of spending goes to programs.

Program 95%Management 5%Fundraising 0%

Governance

3
board members
100%
independent
–Conflict-of-interest policy–Whistleblower policy–Document retention✓Board reviewed the 990–Audited financials

Public support

97%

Share of support from the public (Schedule A) — the basis for its public-charity status.

Footprint & structure

Files a return copy in 1 state

PA

Screen this organization

A dated, signed PDF of the compliance screen for EYE TUMOR RESEARCH FOUNDATION INC: IRS status (Business Master File, Publication 78, auto-revocation), the OFAC sanctions lists, the Internal Revenue Bulletin, and California registration, with the Rev. Proc. 2018-32 §8.01 reliance elements stated element by element. Generated from the current files at the moment you download it.

A paid feature, included from the $75 plan up. Sign in to download.

Screens are triage, not determinations; a source that cannot be read reports not screened, never clear. Screen this nonprofit · How the screen works · on the API as GET /api/screening/{ein}?format=pdf

Questions and answers

Who funds EYE TUMOR RESEARCH FOUNDATION INC?
EYE TUMOR RESEARCH FOUNDATION INC (Pennsylvania) receives grants from 7 organizations whose IRS filings report $145,478 to it, the largest being FILKINS FAMILY FOUNDATION ($76,145). 6 of them have funded it in more than one year.
How many funders does EYE TUMOR RESEARCH FOUNDATION INC have?
IRS filings report 7 organizations giving $145,478 in grants to EYE TUMOR RESEARCH FOUNDATION INC, 6 of which have funded it in more than one year.
Who is the largest funder of EYE TUMOR RESEARCH FOUNDATION INC?
FILKINS FAMILY FOUNDATION is the largest funder on record, with $76,145 in grants. The full list of funders is on this page.
How can an organization like EYE TUMOR RESEARCH FOUNDATION INC find more funders?
Start with the funders already giving here, then look at the foundations that back similar organizations in Pennsylvania. The funding by cause and by state pages list the largest funders for a given area and how to approach them.

Play a game about who funds Eye Tumor Research →

These figures are read directly from IRS Form 990 / 990-PF e-file XML: this organization’s own return for FY2024 (financials across 2017–2024), and the filings of 7 funders that report grants to it. “On record” means captured in the filings we have parsed — a funder that does not e-file, or whose grant detail is not itemized, will not appear. Filings run roughly 12–24 months behind. Trends on this page end at FY2023, the last fiscal year that has finished arriving; later years are shown and marked, and move no figure. Data on this page was exported October 14, 2026. What this page cannot tell you · view filing